Eli Lilly and Company retains first place on the 2026 Global Pharmaceutical Innovation Index for the second consecutive year, while rising from sixth to first on the Invention Index. This marks the first time Lilly has led both rankings simultaneously, reflecting strong alignment between commercial performance and pipeline progression.

Full-year revenues grew approximately 45% to $65.2 billion, driven primarily by Mounjaro (tirzepatide) and Zepbound (tirzepatide), which generated combined sales of $36.5 billion. The incretin franchise remains central to performance, supported by clinical data demonstrating superior weight loss versus Wegovy and additional cardiovascular and paediatric type 2 diabetes outcomes. Verzenio (abemaciclib) also contributed $5.7 billion in oncology sales, while R&D investment increased 21% to $13.3 billion.

Building on its core metabolic franchise, Lilly continues to expand across oncology, neuroscience and immunology. The FDA approved Inluriyo (imlunestrant) for ER+, HER2−, ESR1-mutated advanced or metastatic breast cancer, while Jaypirca (pirtobrutinib) received full approval in relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma. In neuroscience, Kisunla (donanemab) secured European marketing authorization for early symptomatic Alzheimer’s disease, with longer-term data supporting sustained slowing of decline. Omvoh (mirikizumab) has also expanded into Crohn’s disease, building on durable outcomes in ulcerative colitis.​